Pernod Ricard to Integrate Malibu-Kahlúa International Brands into the Absolut Company on July 1st, 2009
6.4.2009 13:58:21 CEST | Business Wire | Press release
Pernod Ricard to Integrate Malibu-Kahlúa International Brands into the Absolut Company on July 1 st , 2009
Regulatory News:
Following the successful acquisition of Allied Domecq in 2005 and since its creation in 2006, Malibu-Kahlúa International (MKI), a subsidiary of Pernod Ricard (Paris:RI), has created strong marketing foundations for Malibu, and its two liqueur brands Kahlúa and Tia Maria.
Malibu is the number one coconut-flavoured rums in the world, sold in more than 150 countries. Kahlúa and Tia Maria are the Group two coffee liqueurs, Kahlúa being the world’s leader in its category.
Recognizing the need to significantly increase the level of support behind these dynamic brands and to maximise efficiency, Pernod Ricard has decided to leverage the resources of The Absolut Company (TAC), the Swedish subsidiary in charge of the leading brand of Premium Vodka, Absolut, which offers many synergies.
As a result, the Malibu-Kahlúa International brands will be consolidated within The Absolut Company and will be managed out of Stockholm, Sweden effective with the new fiscal year 2009/10, July 1st , 2009.
About Pernod Ricard
Created by the merger of Pernod and Ricard (1975), the Group has
undergone sustained development, based on both organic growth and
acquisitions.
The purchase of part of Seagram (2001), the
acquisitions of Allied Domecq (2005) and recently of Vin & Sprit (2008)
have made Pernod Ricard the world’s co-leader in wines and spirits with
sales of € 6,589 million in 2007/08.
Pernod Ricard holds one
of the most prestigious brand portfolios in the sector: ABSOLUT Premium
Vodka, Ricard pastis, Ballantine’s, Chivas Regal and The Glenlivet
Scotch whiskies, Jameson Irish Whiskey, Martell cognac, Havana Club rum,
Beefeater gin, Kahlúa and Malibu liqueurs, Mumm and Perrier-Jouët
champagnes, as well Jacob’s Creek and Montana wines.
The
Group favours a decentralised organisation, with 7 Brand Owners and 70
Distribution Companies established in each key market, and employs a
workforce of more than 19,300 people.
Pernod Ricard is
strongly committed to a sustainable development policy and encourages
responsible consumption.
Pernod Ricard is listed on the NYSE
Euronext exchange (Ticker: RI; ISIN code: FR0000120693) and is a member
of the CAC 40 index.
Shareholders’ agenda: 2008/09 3rd Quarter sales– Thursday 30 April 2009
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact:
Pernod Ricard
Francisco de la VEGA / Communication VP
Tel:
+33 (0)1 41 00 40 96
or
Florence TARON / Press Relations
Manager
Tel: +33 (0)1 41 00 40 88
or
Denis FIEVET /
Financial Communication - Investor Relations VP
Tel: +33 (0)1 41 00
41 71
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom